The role of high-dose chemotherapy in the treatment of testicular cancer

References

• Flechon A, Culine S, Droz JP. Intensive and timely chemotherapy, the key of success in testicular cancer. Crit Rev Oncol Haematol. 2001;37:35–46.
   PubMed Web of Science ®Google Scholar
• International Germ Cell Cancer Consensus Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603.
   PubMed Web of Science ®Google Scholar
• Krege S, Beyer J, Souchon R, et al; European Consensus Conference on diagnosis and treatment of germ cell cancer: a report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53:497–513.
   PubMed Web of Science ®Google Scholar
• Loehler PJ, Godin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Harstrick A, Beyer J, et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ-cell tumors. Semin Oncol. 1998;25:24–32.
   PubMed Web of Science ®Google Scholar
• Horwich A, Dearnaley DP, Norman A, Nicholls J, Hendry WF. Accelerated chemotherapy for poor prognosis germ-cell tumors. Eur J Cancer. 1994;11:1607–1611.
   Google Scholar
• Feldman DR, Bosl G, Sheinfeld J. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672–684.
   PubMed Web of Science ®Google Scholar
• Droz JP, Pico JL, Ghosn M, et al. A phase Ii trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non-seminomatous germ-cell tumors. Bull Cancer. 1992;79:497–507.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazudmar M, Lyn P, et al. High-dose carboplatin, etoposide and cyclophosphamide in first-line therapy for poor-risk germ cell tumors. J Clin Oncol. 1996;14:2546–2552.
   PubMed Web of Science ®Google Scholar
• Decatris MP, Wilkinson PM, Welch RS, et al. High-dose chemotherapy with autologous hematopoietic support in poor-risk nonseminomatous germ cell tumors: an effective first-line therapy with minimal toxicity. Ann Oncol. 2000;11:427–434.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B, et al; Long-term results of first-line sequential high-dose etoposide, ifosfamide and cisplatin chemotherapy plus autologous stem-cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–4091.
   PubMed Web of Science ®Google Scholar
• Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ cell tumors: mature results of a randomized trial. Eur J Urol. 2007;51:739–748.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Necchi A, Nicolai N, et al. High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment in advanced poor prognosis germ cell tumors: a multicenter phase III Italian study. Eur J Cancer. 2009;7(Suppl 2):422.
   Google Scholar
• Bokemeyer C, Kollmannsberger C, Meisner C, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched pair analysis. J Clin Oncol. 1999;17:3450–3456.
   PubMed Web of Science ®Google Scholar
• Mazudmar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol. 2001;19:2534–2541.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous tumors. J Clin Oncol. 2004;22:3868–3871.
   PubMed Web of Science ®Google Scholar
• Murphy BA, Motzer RJ, Mazudmar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage therapy. Cancer. 1994;73:2520–2526.
   PubMed Web of Science ®Google Scholar
• Oloffson S, Dahl O, Jerkeman M, et al. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): a report from the Swedish Norwegian Testicular Cancer Group SWENOTECA. J Clin Oncol. 2009;27:15s.
   Web of Science ®Google Scholar
• Loehler PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;13:1170–1176.
   Google Scholar
• McCaffrey JA, Mazudmdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumor: response and survival. J Clin Oncol. 1997;15:2559–2554.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE, Roth BJ. Management of recurrent testicular germ cell tumors. The Oncologist. 2007;12:51–61.
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol. 2005;16:1152–1159.
   PubMed Web of Science ®Google Scholar
• Broun ER, Nichols CR, Gize CK, Hromas K, Schacht B, Einhorn LH. Tandem high-dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ-cell cancer. Cancer. 1997;79:1605–1610.
   PubMed Web of Science ®Google Scholar
• Horwich A, Wilson C, Cornes P, Gildersleve J, Dearnaley D. Increasing the dose-intensity of chemotherapy in poor-prognosis metastatic nonseminoma. Eur Urol. 1993;23:219–222.
   PubMed Web of Science ®Google Scholar
• Flechon A, Biron P, Droz JP. High-dose chemotherapy with haematopoietic stem cell support in germ cell tumor patient treatment: the French experience. Int J Cancer. 1999;83:844–847.
   PubMed Web of Science ®Google Scholar
• Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched pair analysis. Ann Oncol. 2002;13:599–605.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazudmar M, Bosl GJ, et al. High-dose carboplatin, etoposide and cyclophosphamide for patients with refractory germ-cell tumors: treatemnt results and ptognostic factors for survival anf toxicity. J Clin Oncol. 1996;14:1098–1105.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–1180.
   PubMed Web of Science ®Google Scholar
• Rosti G, De Giorgi U, Salvioni R, et al. Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patients. Cancer. 2002;95:309–315.
   PubMed Web of Science ®Google Scholar
• Rick O, Beyer J, Kingreen D, et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer. 1998;34:1883–1888.
   PubMed Web of Science ®Google Scholar
• McNeish IA, Kanfer EJ, Haynes R, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumors. Br J Cancer. 2004;90:1169–1175.
   PubMed Web of Science ®Google Scholar
• Margolin KA, Doroshow JH, Frankel P, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue fro relapsed germ cell cancer. Biol Bone Marrow Transplant. 2005;11:903–911.
   PubMed Web of Science ®Google Scholar
• Rick O, Beyer J, Hartmann JT, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell tumours. J Clin Oncol. 2001;19:81–88.
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2004;22:3713–3719.
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14:2638–2645.
   PubMed Web of Science ®Google Scholar
• Vaena DA, Abonour R, Einhorn LH, et al. Long-term survival after high-dose chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol. 2003;21:4100–4104.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–348.
   PubMed Web of Science ®Google Scholar